PMID- 26869491
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Feb 12
TI  - Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with 
      Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.
PG  - 20894
LID - 10.1038/srep20894 [doi]
LID - 20894
AB  - RNF2 (ring finger protein 2) is frequently overexpressed in several types of 
      human cancer, but the status of RNF2 amplification and expression in urothelial 
      carcinoma of the bladder (UCB) and its clinical/prognostic significance is 
      unclear. In this study, immunohistochemical analysis and fluorescence in situ 
      hybridization (FISH) were used to examine the expression and amplification of 
      RNF2 in 184 UCB patients after radical cystectomy. Overexpression of RNF2 was 
      observed in 44.0% of UCBs and was found to significantly associate with shortened 
      overall and cancer-specific survival (P < 0.001). In different subsets of UCBs, 
      RNF2 overexpression was also identified as a prognostic indicator in patients 
      with pT1, pT2, pN(-), and/or negative surgical margins (P < 0.05). Importantly, 
      RNF2 overexpression together with pT status and surgical margin status provided 
      significant independent prognostic parameters in multivariate analysis 
      (P < 0.01). FISH results showed amplification of RNF2 in 8/79 (10.1%) of 
      informative UCB cases. Additionally, RNF2 overexpression was significantly 
      associated with RNF2 gene amplification (P = 0.004) and cell proliferation 
      (P = 0.003). These findings suggested that overexpression of RNF2, as examined by 
      immunohistochemical analysis, might serve as a novel prognostic biomarker and 
      potential therapeutic target for UCB patients who undergo radical cystectomy.
FAU - Li, Xiang-Dong
AU  - Li XD
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Chen, Si-Liang
AU  - Chen SL
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Dong, Pei
AU  - Dong P
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Chen, Jie-Wei
AU  - Chen JW
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Wang, Feng-Wei
AU  - Wang FW
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Guo, Sheng-Jie
AU  - Guo SJ
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Jiang, Li-Juan
AU  - Jiang LJ
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Zhou, Fang-Jian
AU  - Zhou FJ
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Xie, Dan
AU  - Xie D
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.
FAU - Liu, Zhuo-Wei
AU  - Liu ZW
AD  - State Key Laboratory of Oncology in South China; Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
AD  - Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160212
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Ki-67 Antigen)
RN  - EC 2.3.2.27 (Polycomb Repressive Complex 1)
RN  - EC 2.3.2.27 (RNF2 protein, human)
SB  - IM
MH  - Cell Proliferation
MH  - Cohort Studies
MH  - *Cystectomy
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Ki-67 Antigen/metabolism
MH  - Male
MH  - Middle Aged
MH  - Polycomb Repressive Complex 1/genetics/*metabolism
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Regression Analysis
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/genetics/*metabolism/*surgery
MH  - Urothelium/*metabolism/pathology/*surgery
PMC - PMC4751429
EDAT- 2016/02/13 06:00
MHDA- 2016/12/27 06:00
PMCR- 2016/02/12
CRDT- 2016/02/13 06:00
PHST- 2015/10/23 00:00 [received]
PHST- 2016/01/11 00:00 [accepted]
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
PHST- 2016/02/12 00:00 [pmc-release]
AID - srep20894 [pii]
AID - 10.1038/srep20894 [doi]
PST - epublish
SO  - Sci Rep. 2016 Feb 12;6:20894. doi: 10.1038/srep20894.